Incyte said a Phase II study showed that INCB28050, its drug candidate for rheumatoid arthritis, was well-tolerated and effective in boosting the score of certain measures for the severity of the condition when administered in three doses for three months. The biotech firm received a milestone payment of $30 million from Eli Lilly and Co.

Full Story:

Related Summaries